Abstract
A potential strategy to alleviate the aggregation of intrinsically disordered proteins (IDPs) is to maintain the native functional state of the protein by small molecule binding. However, the targeting of the native state of IDPs by small molecules has been challenging due to their heterogeneous conformational ensembles. To tackle this challenge, we applied a high-throughput chemical microarray surface plasmon resonance imaging screen to detect the binding between small molecules and monomeric full-length Tau, a protein linked with the onset of a range of Tauopathies. The screen identified a novel set of drug-like fragment and lead-like compounds that bound to Tau. We verified that the majority of these hit compounds reduced the aggregation of different Tau constructs in vitro and in N2a cells. These results demonstrate that Tau is a viable receptor of drug-like small molecules. The drug discovery approach that we present can be applied to other IDPs linked to other misfolding diseases such as Alzheimer’s and Parkinson’s diseases.
Keywords: Alzheimer’s disease, drug discovery, high throughput screening, inhibitor, protein aggregation, tau, taupathies, therapeutic.
Current Alzheimer Research
Title:Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies
Volume: 12 Issue: 9
Author(s): Marcus Pickhardt, Thomas Neumann, Daniel Schwizer, Kari Callaway, Michele Vendruscolo, Dale Schenk, Peter St. George-Hyslop, Eva M. Mandelkow, Christopher M. Dobson, Lisa McConlogue, Eckhard Mandelkow and Gergely Toth
Affiliation:
Keywords: Alzheimer’s disease, drug discovery, high throughput screening, inhibitor, protein aggregation, tau, taupathies, therapeutic.
Abstract: A potential strategy to alleviate the aggregation of intrinsically disordered proteins (IDPs) is to maintain the native functional state of the protein by small molecule binding. However, the targeting of the native state of IDPs by small molecules has been challenging due to their heterogeneous conformational ensembles. To tackle this challenge, we applied a high-throughput chemical microarray surface plasmon resonance imaging screen to detect the binding between small molecules and monomeric full-length Tau, a protein linked with the onset of a range of Tauopathies. The screen identified a novel set of drug-like fragment and lead-like compounds that bound to Tau. We verified that the majority of these hit compounds reduced the aggregation of different Tau constructs in vitro and in N2a cells. These results demonstrate that Tau is a viable receptor of drug-like small molecules. The drug discovery approach that we present can be applied to other IDPs linked to other misfolding diseases such as Alzheimer’s and Parkinson’s diseases.
Export Options
About this article
Cite this article as:
Pickhardt Marcus, Neumann Thomas, Schwizer Daniel, Callaway Kari, Vendruscolo Michele, Schenk Dale, George-Hyslop St. Peter, Mandelkow M. Eva, Dobson M. Christopher, McConlogue Lisa, Mandelkow Eckhard and Toth Gergely, Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/156720501209151019104951
DOI https://dx.doi.org/10.2174/156720501209151019104951 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimers Disease, Depression, and Parkinsons Disease
Current Bioactive Compounds Development of BACE1 Inhibitors for Alzheimers Disease
Current Medicinal Chemistry Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hyperhomocysteinaemia: A Critical Review of Old and New Aspects
Current Drug Metabolism Fluorogold Induces Persistent Neurological Deficits and Circling Behavior in Mice Over-Expressing Human Mutant Tau
Current Neurovascular Research AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Cognitive Dysfunction in FMR1 Premutation Carriers
Current Psychiatry Reviews Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science 18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features
Current Alzheimer Research Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Preparation and Characterization of Methylene blue Nanoparticles for Alzheimer's Disease and Other Tauopathies
Current Drug Delivery Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Histamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases
Current Topics in Medicinal Chemistry Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease
Current Topics in Medicinal Chemistry Efficient Synthesis and Discovery of Schiff Bases as Potent Cholinesterase Inhibitors
Medicinal Chemistry Involvement of Gaucher Disease Mutations in Parkinson Disease
Current Protein & Peptide Science